GFH925

DRUG2 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., Genfleet Therapeutics (Shanghai) Inc.

Conditions

Advance Non-small Cell Lung CancerKRAS G12C

Phase 1

A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

CompletedNCT05005234

Innovent Biologics (Suzhou) Co. Ltd.KRAS G12C

Start: 2021-09-13End: 2024-12-20Updated: 2025-11-17

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

CompletedNCT05756153

Genfleet Therapeutics (Shanghai) Inc.Advance Non-small Cell Lung Cancer

Start: 2023-04-25End: 2025-04-30Updated: 2025-08-12

Related Papers

Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRAS<sup>G12C</sup> inhibitor-naïve Chinese patients with KRAS<sup>G12C</sup>-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies.

2025-07-252 citations

KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.

Journal of Clinical Oncology2024-06-0523 citations

Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRAS<sup>G12C</sup> mutation: Preliminary results from a pooled analysis of two phase I studies.

Journal of Clinical Oncology2023-06-018 citations

Abstract CT030: Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study

Cancer Research2023-04-1411 citations

Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.

Journal of Clinical Oncology2022-06-0110 citations